- Home
- PRGO vs SUPN Comparison
PRGO vs SUPN Comparison
Compare PRGO & SUPN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PRGO
- SUPN
- Stock Information
- Founded
- PRGO 1887
- SUPN 2005
- Country
- PRGO Ireland
- SUPN United States
- Employees
- PRGO N/A
- SUPN N/A
- Industry
- PRGO Biotechnology: Pharmaceutical Preparations
- SUPN Biotechnology: Pharmaceutical Preparations
- Sector
- PRGO Health Care
- SUPN Health Care
- Exchange
- PRGO Nasdaq
- SUPN Nasdaq
- Market Cap
- PRGO 3.1B
- SUPN 2.6B
- IPO Year
- PRGO 1991
- SUPN 2012
- Fundamental
- Price
- PRGO $21.13
- SUPN $44.80
- Analyst Decision
- PRGO Buy
- SUPN Buy
- Analyst Count
- PRGO 4
- SUPN 2
- Target Price
- PRGO $33.00
- SUPN $43.00
- AVG Volume (30 Days)
- PRGO 1.5M
- SUPN 654.2K
- Earning Date
- PRGO 11-05-2025
- SUPN 11-03-2025
- Dividend Yield
- PRGO 5.45%
- SUPN N/A
- EPS Growth
- PRGO N/A
- SUPN 1411.53
- EPS
- PRGO N/A
- SUPN 1.14
- Revenue
- PRGO $4,326,100,000.00
- SUPN $665,125,000.00
- Revenue This Year
- PRGO $2.28
- SUPN $4.84
- Revenue Next Year
- PRGO $0.54
- SUPN $17.69
- P/E Ratio
- PRGO N/A
- SUPN $38.93
- Revenue Growth
- PRGO N/A
- SUPN 5.55
- 52 Week Low
- PRGO $21.03
- SUPN $29.16
- 52 Week High
- PRGO $30.93
- SUPN $46.79
- Technical
- Relative Strength Index (RSI)
- PRGO 27.65
- SUPN 58.16
- Support Level
- PRGO $22.00
- SUPN $43.44
- Resistance Level
- PRGO $22.58
- SUPN $46.72
- Average True Range (ATR)
- PRGO 0.54
- SUPN 1.08
- MACD
- PRGO -0.09
- SUPN -0.48
- Stochastic Oscillator
- PRGO 3.39
- SUPN 40.60
About PRGO Perrigo Company plc
Perrigo is one of the largest consumer health companies in the world. Since 2018, Perrigo divested its animal health and generic pharmaceuticals businesses to solely focus on consumer self-care. In North America (two thirds of total sales), the firm's product mix is anchored in private-label consumer health goods, which are sold to major retailers like Walmart, Amazon, Costco, and CVS. Perrigo also plays in Europe, Australia, and parts of Asia where it primarily generates revenue through its national brands, including Compeed, Solpadeine, Coldrex, and ellaOne.
About SUPN Supernus Pharmaceuticals Inc.
Supernus Pharmaceuticals Inc is a specialty pharmaceutical company. The company is engaged in developing and commercializing products for the treatment of central nervous system diseases, including neurological and psychiatric disorders. Its diverse neuroscience portfolio includes approved treatments for epilepsy, migraine, attention-deficit hyperactivity disorder (ADHD), hypomobility in Parkinson's Disease (PD), cervical dystonia, chronic sialorrhea, dyskinesia in PD patients receiving levodopa-based therapy, and drug-induced extrapyramidal reactions in adult patients. The company's products include Trokendi XR, Oxtellar XR, Qelbree, APOKYN, XADAGO, MYOBLOC, GOCOVRI, and Osmolex ER.